TriSalus Life Sciences, Inc.
NASDAQ:TLSIMedical - Devices
+$0.02 today
- Market cap
- $151.16M
- Beta
- 0.49
- P/E (TTM)
- -7.4
- EPS (TTM)
- -$0.53
Volume 0.40M
Average 0.38M
TLSI Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
TriSalus Life Sciences, Inc.NASDAQ: TLSI
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue dips below year-ago levels
Q1 FY2026 cost of revenue of $1.23M fell 17.7% year over year, behind the +44.8% change in trailing-twelve-month cost of revenue. Sequentially, it fell 30.2% from the prior quarter. Over 3 fiscal years it compounded at +45.6% a year.
Context
- Cost of revenue amounted to 15.4% of revenue in FY2025, up 1.5 pp from a year earlier.
- Cost of revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -17.7% toward the trailing-twelve-month pace of +44.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 6.97M USD
- Year-over-year change
- +69.8%
- 4-year CAGR
- +55.4%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.97M | +69.8% |
| FY2024 | 2024-12-31 | 4.1M | +57.5% |
| FY2023 | 2023-12-31 | 2.61M | +15.4% |
| FY2022 | 2022-12-31 | 2.26M | +89.3% |
| FY2021 | 2021-12-31 | 1.19M | — |
Cost of Revenue vs competitors
How TLSI compares with its peers on the latest reported figures
- TLSI's LTM Mar 2026 cost of revenue of $6.7M is the 6th highest of the 11 companies compared; the peer median is $16.02M.
- Its year-over-year change of +44.8% is the 3rd highest of 10, against a peer median of +17.1%.
- Cost of revenue amounts to 14.9% of revenue for TLSI, versus a peer median of 50.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $78.91M | +141.8% | +70.6% | 52.0% | |
| LTM Mar 2026 | $52.61M | +30.6% | +4.4% | 49.1% | |
| LTM Mar 2026 | $47.41M | +110.1% | +65.9% | 41.7% | |
| LTM Mar 2026 | $31.55M | +5.2% | +26.7% | 54.7% | |
| LTM Dec 2025 | $25.81M | +17.4% | +18.6% | 198.2% | |
| LTM Mar 2026 | $6.7M | +44.8% | +45.6% | 14.9% | |
| LTM Mar 2026 | $6.23M | -13.4% | +6.9% | 19.3% | |
| LTM Mar 2026 | $5.46M | +17.1% | +9.4% | 28.9% | |
| LTM Mar 2026 | $2.63M | — | — | 426.2% | |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | $1.33M | +13.5% | -8.4% | 71.7% |
| LTM Mar 2026 | $823K | -40.6% | -64.8% | 27.8% | |
| Peer median (excluding TLSI) | $16.02M | +17.1% | +9.4% | 50.6% | |
Competitors are the stored peer set for TLSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 8.4M | 12.4M | 18.51M | 29.43M | 45.15M |
| Cost of Revenue | 1.19M | 2.26M | 2.61M | 4.1M | 6.97M |
| Gross Profit | 7.21M | 10.14M | 15.91M | 25.33M | 38.19M |
| Gross Margin | 85.8% | 81.8% | 85.9% | 86.1% | 84.6% |
| Research & Development | 14.22M | 21.36M | 29.84M | 17.69M | 14.97M |
| Selling, General & Admin | 17.02M | 25.22M | 40.55M | 43.81M | 50.17M |
| Operating Expenses | 31.24M | 46.58M | 70.38M | 61.49M | 65.13M |
| Depreciation & Amortization | 464K | 414K | 684K | 744K | 626K |
| EBITDA | (26.62M) | (46.76M) | (58.65M) | (32.39M) | (33.05M) |
| EBITDA Margin | -316.8% | -377.2% | -316.9% | -110.0% | -73.2% |
| Operating Income | (24.03M) | (36.44M) | (54.48M) | (36.17M) | (26.95M) |
| Operating Margin | -286.1% | -293.9% | -294.3% | -122.9% | -59.7% |
| Interest Income | 0 | 180K | 431K | 404K | 555K |
| Interest Expense | 1.76M | 1K | 16K | 3.09M | 5.54M |
| Other Income / Expenses | (4.81M) | (10.74M) | (4.88M) | 6.13M | (12.27M) |
| Income Before Tax | (28.84M) | (47.18M) | (59.35M) | (30.04M) | (39.22M) |
| Pre-Tax Margin | -343.3% | -380.5% | -320.6% | -102.1% | -86.9% |
| Income Tax Expense | 3K | 9K | 9K | 6K | 7K |
| Net Income | (28.85M) | (47.19M) | (59.36M) | (33.23M) | (39.23M) |
| Net Margin | -343.4% | -380.6% | -320.7% | -112.9% | -86.9% |
| EPS (Basic) | (0.92) | (1.59) | (2.23) | (1.25) | (1.84) |
| EPS (Diluted) | (0.92) | (1.59) | (2.23) | (1.25) | (1.84) |
| Weighted Avg Shares | 31.25M | 29.61M | 26.47M | 26.5M | 49.19M |
| Weighted Avg Shares (Diluted) | 31.25M | 29.61M | 26.47M | 26.5M | 37.9M |
TriSalus Life Sciences, Inc.
NASDAQ:TLSI
Intrinsic Alpha fair value
Locked
Current Price
$2.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.